Group 1 - The core viewpoint of the article highlights the strategic partnership between Suzhou Yusen Pharmaceutical Co., Ltd. and Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. to develop innovative traditional Chinese medicine products [1] - The collaboration focuses on two innovative TCM products, "Xiaoxian Zhihuan Oral Liquid" and "Tiandan Dingxuan Granules," aiming to enhance the research and industrialization of TCM [1] - The partnership aims to integrate technology, clinical, and industrial resources to cover the entire chain of preclinical research, clinical research, registration, and post-market promotion [1] Group 2 - Yusen Pharmaceutical emphasizes the combination of technology and industry, creating a complete innovation loop from laboratory research to clinical application [2] - Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. plans to deepen exploration in areas such as international registration of TCM and the development of health products [2] - The collaboration is expected to contribute to the construction of a Sino-Sichuan TCM innovation corridor, facilitating the global market entry of Chinese TCM new drugs [2]

8月22日，苏州玉森新药开发有限公司与四川省现代中药创新技术有限公司在苏州正式签署产品合作协 议，宣布就"消腺止鼾口服液"与"天丹定眩颗粒"两大中药1.1类创新药展开深度合作，并隆重举行签约 仪式。此次合作标志着双方在中医药创新领域迈出关键步伐，将共同推动中药新药研发与产业化进程。 消腺止鼾口服液针对儿童腺样体肥大，以桔梗、鱼腥草等组方清热化痰、调畅气机，临床定位3—7岁痰 热内蕴患儿，兼具疗效与安全性，填补中成药市场空白。天丹定眩颗粒由经典名方化裁而成，专注风痰 上扰型眩晕症的治疗，以天麻、丹参为核心，兼具化痰息风与活血通络之效，满足老龄化趋势下眩晕治 疗需求。两产品均以创新处方和临床优势，分别瞄准40亿腺样体肥大及12亿眩晕市场，体现中药"标本 兼治、副作用小"的特色，预计2026年陆续进入临床，为儿科与慢病领域提供安全高效的新选择。 玉森新药董事长玄振玉教授指出："此次合作不仅是技术与产业的结合，更是跨区域创新生态的协同。 我们将基于玉森新药中药创新药现代化研究的深厚积累，以及四川省现代中药创新技术公司的产业化优 势，共同构建从实验室研究到临床应用的完整创新闭环。" 四川省现代中药创新技术有限公司董事长 ...